MRK  Merck & Company Inc.

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

153.31B

Vuru Grade

54.36/100

Current Price

$55.24
+0.40 (+0.73%)

Growth Price

$54.27
Fairly valued

Stability Price

$20.46
Overvalued by 62.97%

Company Metrics

  • P/E 35.41
  • P/S 3.85
  • P/B 3.41
  • EPS 1.56
  • Cash ROIC 12.97%
  • Cash Ratio 0.70
  • Dividend 1.84 / 3.36%
  • Avg. Vol. 10.06M
  • Shares 2.78B
  • Market Cap. 153.31B

Company Description

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company's Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, ... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

How High Can Merck & Co., Inc. (NYSE:MRK) Stock Go? Analysts Hold $61.65 Price ...
The Point Review - 11 hours ago
Merck & Co., Inc. (NYSE:MRK) shares traded -1.60% during the most recent session. Wall Street analysts covering the stock are projecting that the stock will reach $61.65 within the next 52-weeks.
Pfizer Inc Vs. Merck & Co: Which Pharmaceutical Giant Should You Buy? - Seeking Alpha
Merck And Pfizer Earnings: Will They Beat Expectations Again? - Benzinga
Merck & Co. Inc (MRK) Closes 0.84% Up on the Day for May 02
Equities.com - 3 hours ago
Merck & Co. Inc currently has a total float of 2.78 billion shares and moves 8.65 million a day, on average. The stock opened at $54.85 on May 02 and traded between a low of $54.70 and a high of $55.36.
Earnings: Drug Makers Merck And Pfizer Report Q1 Results
Benzinga - 10 hours ago
Merck & Co., Inc. (NYSE: MRK) had a busy quarter with a handful of approvals by the U.S. Food and Drug Administration for drugs tied to diseases ranging from hepatitis C to Hodgkin lymphoma.
One Put, One Call Option To Know About for Merck & Co.
Nasdaq - 8 hours ago
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc (Symbol: MRK). So this week we highlight one interesting put contract, and one interesting call contract, from the ...
Merck & Co. Inc. (MRK) Analysts Recommendations and Insider Trading
Zergwatch - Apr 29, 2016
Merck & Co. Inc. (MRK) stock last traded at $55.74 and lots of rating firms seem to have a target price set on the stock.
Are Analysts Bullish Merck & Co., Inc. (NYSE:MRK) After Last Week? - Franklin Independent
Traders Alert: Merck & Co. Inc. (NYSE:MRK), Centene Corp. (NYSE:CNC) - Wall Street 24
Merck & Co. Inc (MRK) Closes 1.01% Down on the Day for April 28
Equities.com - Apr 28, 2016
Dow Jones component Merck & Co. Inc (MRK) saw its stock move -1.01% to $55.74, representing a per-share move of $0.57, on volume of 9.01 million shares for Thursday.
Merck & Co. Inc (MRK) Closes 0.48% Up on the Day for April 27
Equities.com - Apr 27, 2016
Dow Jones component Merck & Co. Inc (MRK) saw its stock move 0.48% to $56.31, representing a per-share move of $0.27, on volume of 6.84 million shares for Wednesday.
Analyst's Review to Watch: Merck & Co. Inc (MRK)
CWRU Observer - Apr 29, 2016
Merck & Co. Inc. (MRK) shares closed at price of $55.74 by scoring -1.01% during its last trade. The shares of this company currently has mean rating of Outperform while 3 analysts have recommended the shares as BUY, 6 recommended as OUTPERFORM ...
Merck & Co. Inc (MRK) Closes 0.32% Down on the Day for April 26
Equities.com - Apr 26, 2016
Dow Jones component Merck & Co. Inc (MRK) saw its stock move -0.32% to $56.04, representing a per-share move of $0.18, on volume of 7.2 million shares for Tuesday.
Advaxis, Inc. (NASDAQ:ADXS) and Merck & Co., Inc. (NYSE:MRK) combine to ...
Market Exclusive - Apr 6, 2016
The teaming up of Advaxis, Inc. (NASDAQ:ADXS) and Merck & Co., Inc. (NYSE:MRK) has resulted in the completion of the first two dose-escalation cohorts for the KEYNOTE-046 prostate cancer trial.
Analyst's Report Recap: Merck & Co. Inc. (MRK) - CWRU Observer
Merck & Co., Inc. (MRK) Position Cut by Henderson Group PLC - The Vista Voice